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Objective: Optimum strategy for salvage in patients with acutely decompensated end-stage heart failure and se-
vere multiorgan dysfunction is complex. We present our experience with prolonged CentriMag (Levitronix, Wal-
tham, Mass) support for transitioning patients after successful salvage from bridge to decision directly to
transplant.
Methods: Records of patients who underwent salvage with a CentriMag as bridge to decision and later to trans-
plant were reviewed. Between June 2003 and June 2008, 4 patients in cardiogenic shock from acute decompen-
sated end-stage heart failure and multiorgan dysfunction underwent salvage with biventricular CentriMag as
bridge to decision. Three were male. Mean age was 39.3 years (range 24–52 years). Three had dilated cardiomy-
opathy; 1 had ischemic cardiomyopathy. All had preoperative mechanical ventilation, large doses of multiple ino-
tropes, and intra-aortic balloon support. All also had acute liver and renal failure and metabolic acidosis.
Results:After mean postimplant period of 43 days (range 7–70 days), patients had reversal of end-organ dysfunc-
tion; after mean waiting time of 31 days (range 21–67 days), all were transplant listed. Mean mechanical circu-
latory support was 87.7 days (range 26–105 days). No thromboembolic or neurologic events or mechanical
failures occurred. Posttransplant mean ventilation and intensive care unit stay were 2 and 4 days (ranges 1–4
and 3–7 days), respectively. All patients were discharged home and remain alive and well.
Conclusion: CentriMag use as long as 3 months appears to be safe and cost-effective for bridging selected pa-
tients directly to transplant after salvage. Further clinical experience is still needed.T
XThe CentriMag (Levitronix, Waltham, Mass) ventricular as-
sist device (VAD) was initially used for short-term ventric-
ular support in postcardiotomy failure after routine cardiac
surgery, for primary graft dysfunction after heart transplant,
and for salvage as a bridge to decision (BTD) in patients with
severe decompensated end-stage heart failure (DESHF), as
has previously been reported.1-6 In this report, we describe
our experience with a subset of moribund patients who
had initial salvage with this device as a BTD for longer
than 3 months, leading directly to transplant.
MATERIALS AND METHODS
Eighty-patients received CentriMag VAD support at our institution between
June 2003 and August 2008. We reviewed the records of patients with acute car-
diogenic shock from advanced heart failure who underwent salvage with a Cen-
triMag VAD as a BTD and later a direct bridge to orthotopic heart transplant.
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triMag VAD support at our institution. Twenty-six patients (32.5%) had
postcardiotomy failure, 15 (18.8%) had Levitronix CentriMag right VAD
(RVAD) placement along with a long-term left VAD (LVAD), 16 (20%)
had primary graft dysfunction after heart transplant, and 23 (28.8%) either
had acute presentation for salvage procedure as a BTD or had deteriorating
end-stage heart failure or acute heart failure with multiorgan dysfunction
(MOD) and underwent salvage as a BTD. Three patients of this last group
(3/23) had myocardial recovery and had the VAD explanted, 7 had upgrades
to long–term LVAD (either HeartMate II [Thoratec Corp, Pleasanton, Calif]
or Jarvik 2000 [Jarvik Heart, Inc, New York, NY]) with explantation of the
RVAD, 10 patients died during support, and 4 (the subjects of this study)
had prolonged Levitronix CentriMag support with subsequent bridging di-
rectly to transplant. This report focuses on the last subgroup.
All 4 patients had severe cardiogenic shock from DESHF, sepsis, and
MOD, and all underwent salvage with the CentriMag biventricular VAD
(BiVAD) as a BTD. Three were male and 1 was female. The mean age at
presentation was 39.3 years (range 24–52 years). Three had dilated cardio-
myopathy, and 1 had ischemic cardiomyopathy. The mean body mass index
(BMI) was 22.5 kg/m2 (range 18.7–25.2 kg/m2). All patients were in severe
cardiovascular collapse and receiving large and multiple doses of inotropic
support (more than two inotropes per patient). All patients had intra-aortic
balloon pumps. Three patients also had cardiac cachexia. All were in respi-
ratory failure and had mechanical ventilation. All had acute liver and renal
failure and were in acute metabolic acidosis. Table 1 presents a summary of
the preoperative hemodynamic and metabolic conditions. All patients un-
derwent salvage with an off-pump CentriMag BiVAD as a BTD. In 1
case, the pump was inserted during cardiopulmonary resuscitation and
open cardiac massage.
In all cases, an LVAD was first inserted, and nitric oxide was given to all
the patients. If, however, hemodynamic and echocardiographic evidence ofardiovascular Surgery c Volume 138, Number 1 227
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BMI ¼ body mass index
BiVAD ¼ biventricular assist device
BTD ¼ bridge to decision
DESHF ¼ decompensated end-stage heart failure
ICU ¼ intensive care unit
LVAD ¼ left ventricular assist device
MOD ¼ multiple-organ dysfunction
RVAD ¼ right ventricular assist device
VAD ¼ ventricular assist device
right ventricular dysfunction resulting in suboptimal LVAD flow to support
BMI, rising central venous pressure, and a need for large dose of inotropes
to support the right ventricle were observed, an RVAD was inserted. In this
critically ill group of patients, we have a low threshold of BiVAD insertion
rather than isolated LVAD support to allow optimal flow, reduce hepatic
congestion, and secure good renal perfusion.
Surgical Technique
After the chest was opened through a median sternotomy, full heparin-
ization (3 mg/kg) was given. The LVAD and RVAD inflow and outflow
cannulas (32F single-stage malleable venous drainage cannula [Edwards
Lifesciences, Irvine, Calif] for the inflow and 22F elongated 1-piece arterial
cannula [EOPA; Medtronic, Inc, Minneapolis, Minn] for the outflow line)
were introduced through separate skin incisions on the right upper abdom-
inal quadrant for the LVAD and on the left upper abdominal quadrant for the
RVAD. After preparation of double purse-string sutures, the LVAD inflow
and outflow cannulas were placed and secured in the left atrium (intra-atrial
grove) and ascending aorta, respectively. The RVAD inflow and outflow
cannulas were placed in the right atrium and main pulmonary artery, respec-
tively. The positioning of the inflow cannulas in the right and left atria was
directed by transesophageal echocardiography.
Management of VAD and External Circuits
Throughout the period of mechanical circulatory support, the external cir-
cuits and the pump’s head were arbitrarily changed every 4 weeks. Examina-
tion of a number of the first exchanged external circuits and pump heads did
not, however, show clots or structural damage. We therefore decided that we
could safely extend to 6 weeks the period of support without changing the
pump head and external circuit. If any visible fibrin sediments were noted
in the external circuit lines, an earlier exchange of the circuit was pursued.
Anticoagulation Protocol
Full heparinization was given perioperatively and was fully reversed af-
ter establishment of full flow on both VADs and before closure of the chest.
Continuous intravenous heparin was restarted several hours postoperatively
after at least 4 hours without a bleeding event. The dose was adjusted every
4 hours for a target activated partial prothrombin time of 60 to 100 seconds,
other than during the period when the assessment of the heart function was
made, with the pump flow lowered for few hours; then the target activated
partial prothrombin time was 80 to 100 seconds.
Assessment of Cardiac Function During Support
First attempt at weaning from the VAD was performed at 14 postopera-
tive days. The assessment of the cardiac function for potential early myocar-
dial recovery was performed by recording such baseline hemodynamic data
as mean blood pressure, heart rate, right heart pressures, mixed venous sat-
uration, and urinary output during full support, followed by reducing the228 The Journal of Thoracic and Cardiovascular Suflow to a minimum of 1 L/min. During and after 6 to 8 hours of low flow
without inotropes, the hemodynamic, right-heart pressure, and cardiac out-
put studies were performed, as was transthoracic echocardiography.
Patient Management During Support
All patients were managed in the intensive care unit (ICU) by the ICU
nursing team, supervised by the surgeons and mechanical circulatory sup-
port consultant and anesthetists. Continuous presence of the perfusionists
in the ICU was not required. They did, however, review the patients in
the ICU at least once a day to check the technical aspects of the pumps
and were also present during physiotherapy and patient mobilization.
Once multiorgan function was restored with no remaining infection and
the patients were self-ventilating, the patients were transferred to the ward
under the VAD nurses’ care, supervised mainly by the mechanical circula-
tory support cardiologist with surgical input as required. The exchange of
the external circuits was performed electively by the perfusionists under sur-
geon supervision.
RESULTS
The mean duration of CentriMag BiVAD support was
87.7 days (range 26–105) days. The mean RVAD and
LVAD flows were 4.9 and 5.4 L/min (range 4.6–5.5 and
4.5–6.7 L/min), respectively. No patient needed surgical re-
exploration for postimplant bleeding. All patients were no
longer receiving inotropes or intra-aortic balloon pulsation
within the first 48 postoperative hours. Three patients were
extubated within the first 48 postoperative hours. One pa-
tient needed longer-term ventilation through a tracheostomy
because of general weakness and cachexia.
After a mean of 43 days (range 7–70 days) after BiVAD
implantation, all patients showed good clinical recovery
TABLE 1. Preoperative hemodynamic and laboratory data
Mean Range
Blood pressure (mm Hg)
Systolic 76 95–60
Diastolic 53 40–75
Heart rate (beats/min) 99 71–122
Central venous pressure (mm Hg) 17.6 14–21
Pulmonary arterial pressure (mm Hg)
Systolic 82 NA
Diastolic 38 NA
Epinephrine (mg/[kg $min], 3/4 patients) 0.84 0–1.8
Norepinephrine (mg/[kg $min], 1/4 patients) 0.63 0–1.7
Dopamine (mg/[kg $min], 3/4 patients) 4.8 0–7.9
Dobutamine (mg/[kg $min], 1/4 patients) 6.4 0–7.3
Milrinone (mg/[kg $min], 2/4 patients) 0.33 0–0.43
Mechanical ventilation (no.) 4/4 (100%) NA
Intra-aortic balloon pump (no.) 4/4 (100%) NA
White blood cells (cells/mL, no.) 23,133 4300–54,200
Bilirubin (mmol/L) 79.2 18–197
Alkaline phosphatase (IU/L) 93.6 63–135
Alanine aminotransferase (IU/L) 422.8 53–1436
Sodium ion (mmol/L) 130.5 127–134
Potassium ion (mmol/L) 5.6 4.9–6.3
Urea (mmol/L) 13.18 9.2–22
Creatinine (mmol/L) 145 121–253
NA, Not applicable.rgery c July 2009
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fectious or neurologic complications. They were listed for
and directly bridged to transplant. The mean waiting time
for a donor heart was 31 days (range 21–67 days). Donor
mean age was 27.2 years (range 18–40 years). Two donors
were female, and 2 were male. All 4 donors had blood group
O. One donor had died of intracranial bleeding after head in-
juries, 1 with Evans syndrome had died of relapsing myeli-
tis, and 2 had died of subarachnoid hemorrhage related to
arteriovenous malformation. The mean ischemic time was
180 minutes (range 135–220 minutes). The posttransplant
mean duration of ventilation and ICU stay were 2 days
(range 1–4 days) and 4 days (range 3–7 days), respectively.
The posttransplant survival to home discharge was 100%.
All patients remained alive and well at 4, 8, 14, and 25
months of follow-up.
No patients had sternal wound infection; in all cases, how-
ever, the VAD cannula exit sites were managed with surgical
de´bridement and by using a vacuum-assisted closure dress-
ing (KCI Medical Ltd, Kidlington, UK) until complete heal-
ing had been achieved. In 1 patient, a large abdominal wall
defect caused by multiple cannula exit sites and chest drains
needed a skin graft.
Gastrointestinal bleeding from peptic ulcers was seen in 1
patient during mechanical circulatory support, necessitating
a large transfused volume of blood and blood products, re-
peated gastroscopies, and angiographic catheter emboliza-
tion. During this period, the anticoagulation regimen was
stopped for several days without any adverse effects.
There were no instances of pump mechanical failure,
thrombosis, or thromboembolic events. No patient had neu-
rologic complications. All patients underwent ambulation
and mobilization from bed during support in the ICU and
on the ward.
We compared the costs of this group of patients who had
direct bridging to transplant after salvage with those of the
group of patients who underwent salvage with the Levitro-
nix CentriMag device and then upgrade to a long-term de-
vice (such as the HeartMate II) as a bridge to transplant.
The immediate postoperative ICU stays were similar in these
two groups; however, the cost of the Levitronix CentriMag
device was significantly lower than that of the long-term de-
vice. The costs of an additional surgical procedure to per-
form the upgrade were also saved. We also managed to
reduce the ICU stay substantially for patients who had pro-
longed Levitronix CentriMag support by encouraging early
postoperative mobilization and by transferring them to the
ward as soon as possible after reversal of MOD.
DISCUSSION
Our overall experience with CentriMag short-term VAD
use as a BTD has been reported before.1-4 The indications
for using the CentriMag in salvage for patients with acute
decompensated end-stage heart failure, MOD, and infectionThe Journal of Thoracic andwas influenced by the need for quick, and often off-pump,
surgery with a simply operated and relatively inexpensive
VAD that could support both sides of the heart for this
very sick group of patients until there was evidence of the
reversibility of end-organ dysfunction, particularly the neu-
rologic condition. Moreover, the CentriMag had a satisfac-
tory flow for high-BMI patients and provided adequate
organ perfusion, which could effectively restore end-organ
function, as defined at the point when the patients were
self-ventilating with normal hepatic and renal function
with no active infection. Once MOD had been reversed
and there were neither serious neurologic damage, active
sepsis, nor early signs of myocardial recovery, the decision
was made to bridge these patients directly to transplant.
We consider this option to be a cost-effective and superior
alternative to upgrading to a long-term VAD for this sub-
group of patients, mainly because it avoids further surgical
complications that might be associated with another device
being inserted. It also allows a shorter bridging period,
with reduced VAD-related complications. It avoids the
risk of embolic complications during the removal of the of
the VAD cannulas (particularly the left atrial cannula).
Because some time is needed for the patients to recover,
however, and also because of the shortage of donor organs
for transplant, our 4 patients needed longer than 3 months
of mechanical circulatory support before they received
a transplant. During this period, replacements of the sin-
gle-use motor and external circuit of the VADs were suc-
cessfully performed every 6 weeks in the ICU or the
operating room without the need for sedation or surgical in-
tervention.1 This seemed to be a simple and well-tolerated
procedure that allowed us to extend safely the length of me-
chanical circulatory support with this device. During this pe-
riod, we saw high mechanical reliability, with no mechanical
failures or thromboembolic events.
These patients cannot achieve full ambulation, but a policy
of intensive physiotherapy and mobilization while they are in
the ICU, and recently while they are on the ward, has been
applied and shown to be effective. Our recent policy to allow
transfer of these patients to the ward rather than keeping them
in the ICU also has cost-effective implications.
In the Randomized Evaluation of Mechanical Assistance
for the Treatment of Congestive Heart Failure (REMATCH)
trial, patients who were younger than 65 years did better than
the older group of patients.6 Our study group was character-
ized by a relatively young age (mean age was 39.3 years, and
the oldest was 52 years old), which may have had an impact
on successful restoration of multiorgan function, capacity to
ambulate and cooperate with the physiotherapy team, and
potential to become viable transplant candidates. The groups
of patients who survived and did not survive, however, were
too small to draw conclusions.
Direct bridging to transplant after a prolonged period of
mechanical circulatory support (as long as 3 months) provedCardiovascular Surgery c Volume 138, Number 1 229
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had relatively BMIs and common blood groups. For the pa-
tient who shows early signs of myocardial recovery after
a few weeks of mechanical circulatory support or is unlikely
to receive a transplant in the short term (such as a patient
with high BMI, positive panel-reactive antibodies, or un-
common blood group), early consideration should be given
to upgrading the short-term VAD to longer-term VAD sup-
port as soon as the MOD state has reversed with no active
infection and the patient’s nutritional and general conditions
become suitable for further surgery.
CONCLUSIONS
Prolonged use of the Levitronix CentriMag VAD for as
long as 3 months appears to be a relatively safe and cost-ef-
fective procedure for direct bridging of selected patients to
transplant after salvage. Further clinical experience and eval-
uation are still needed.230 The Journal of Thoracic and Cardiovascular SuWe thank Harefield hospital perfusion, VAD nurses, and ICU
and physiotherapy team for their dedicated care of all patients
with VAD.
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